Development of chimeric antigen receptors targeting T-cell malignancies using two structurally different anti-CD5 antigen binding domains in NK and CRISPR-edited T cell lines

DOI: 10.1080/2162402X.2017.1407898

Keywords: anti-cds scFv, chimeric antigen receptor, immunotheraphy, lamprey variable lymphocyte receptor, T-cell lenkemia

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text